INTRODUCTION
More than 200,000 men are diagnosed annually with prostate cancer (PCa) and there are more than 2 million survivors.
1,2 Androgen-deprivation therapy (ADT) is effective palliative treatment for metastatic prostate cancer 3 and improves survival rates in certain clinical settings. These clinical settings include adjuvant ADT for lymph nodepositive disease treated with prostatectomy and pelvic lymphadenectomy 4 or intermediate-or highrisk PCa undergoing radiation therapy. 5, 6 However, ADT use has increased as primary monotherapy in localized disease for men who do not undergo prostatectomy or radiation and for biochemical recurrence after potentially curative treatment. [7] [8] [9] [10] Although there is no evidence that primary ADT (PADT) improves survival rates, 7-9 at least 40% of men older than 65 years who have clinically localized PCa that was initially managed without surgery or radiation received PADT monotherapy between 1998 and 2002. 11, 12 By the early 2000s, PADT was the second most common treatment after radiotherapy for clinically localized PCa among older men. 11, 12 ADT remains widely used despite some decline in use for lowerrisk disease after 2004.
13-15 A recent study reported that one in eight men ages 65 and older who had prostate cancer received PADT, which is discordant with recommended guidelines and costs Medicare an estimated $42 million per year.
can have substantial long-term adverse consequences on the quality and quantity of life. These adverse effects include impaired cognitive function, loss of muscle strength, anemia, 17,18 bone loss or fractures, 19 ,20 coronary heart disease, 21-24 insulin sensitivity, 25 and diabetes mellitus. 22, 24, 26 In 2010, the US Food and Drug Administration notified manufacturers of ADT-injectable agents to add new warnings to their products regarding the potential risks of coronary heart disease and diabetes. 27 Given the aging American population, it is imperative to determine whether these risks outweigh any mortality benefit from PADT.
Three prior observational studies that used cancer registry data linked with Medicare claims (Surveillance, Epidemiology, and End Results [SEER] -Medicare data 28 ) attempted to assess mortality among men who received PADT but not curative intent therapy. These studies showed PADT to have no benefit, 11 potential harm, 29 or possible benefit. 30 However, these studies focused on older men, were unable to account for key clinical prognostic variables likely to confound mortality-risk estimates, or used analytic methods that may not be informative for clinical decision-making.
We assessed the association of PADT with mortality in a diverse cohort of 15,170 men who were diagnosed with clinically localized PCa between 1995 and 2008 and received follow-up through 2010. We selected all-cause mortality as our primary end point because of the possibility of adverse effects of PADT on noncancer mortality. We also conducted a subgroup analysis to discern whether a clinical benefit exists in subgroups of men defined by age at diagnosis or risk of recurrence.
METHODS

Data Sources
We conducted a retrospective cohort study of men who were newly diagnosed with clinically localized PCa and were enrolled in one of three integrated healthcare delivery systems within the HMO Cancer Research Network 31 : Kaiser Permanente Northern California, Kaiser Permanente Southern California, or Henry Ford Health System in Detroit, MI. These health plans have comprehensive information from inpatient and outpatient diagnoses, clinical encounters, laboratory test values (including prostate-specific antigen [PSA] values), pharmacy data, and tumor-registry data.
Study Participants
A total of 60,058 men diagnosed with PCa (per tumor registry data) were assessed for eligibility. Men were excluded in the following order: if they had nonlocalized PCa (defined as disease at clinical stage T4, with any nodal involvement, or with any distant metastasis) or were diagnosed after 2008 (n ϭ 6,705); if they received radiation, radical prostatectomy, or chemotherapy within 1 year after PCa diagnosis (n ϭ 37,808); if they received orchiectomy within 1 year after diagnosis (n ϭ 117); if they received neoadjuvant ADT (radical prostatectomy or radiation therapy within 9 months of first ADT claim; n ϭ 240); or if their records were missing date of death or had other data errors (n ϭ 18). These exclusions resulted in a final cohort of 15,170 men (Appendix Fig A1, online only) . All patients received follow-up through December 2010 or until censoring because of death or disenrollment (median follow-up, 61 months).
Primary Androgen-Deprivation Therapy
ADT was defined as either a gonadotropin-releasing hormone analog (eg, leuprolide, goserelin, or triporelin) or gonadotropin-releasing hormone antagonists (eg, abarelix or degarelix), with or without an oral antiandrogen (flutamide, bicalutamide, or nilutamide) for combined androgen blockade. We defined PADT based on receipt of medical ADT for localized PCa within the first 12 months after initial diagnosis without receipt of radiation or radical prostatectomy. We excluded 117 men who received orchiectomy to focus our comparison on medical ADT, that is, the standard method of ADT delivery in current clinical practice. Among the 15,170 men, 3,435 received PADT and 11,735 received no PADT within the first 12 months. Of the men in the latter group, 2,036 men (17%) who received ADT after 12 months were kept in the cohort to adhere to the principles of intent-to-treat analysis.
Mortality Outcomes
We used International Classification of Diseases 10th revision (ICD-10) codes to measure four outcomes: all-cause mortality, prostate cancer-specific mortality (C619, C61 185), any cancer mortality (C00-C97, D37-D48, 185), and cardiovascular mortality (I05-I99). Information on date and cause of death for health plan members was derived from a combination of clinical databases, linkages with California and Michigan death certificate records, and linkages with Social Security Administration data to ascertain deaths that may have occurred outside California or Michigan.
Independent Variables
We obtained from registry data age at diagnosis, race-ethnicity, year of diagnosis, and diagnosis of prior or subsequent primary cancers other than prostate cancer. We included the key clinical variables that determine PADT use and PCa-related mortality: serum PSA, Gleason score, and clinical T stage. All clinical variables were derived from the health plan tumor registries that operate similarly to the National Cancer Institute SEER registries and are the primary sources for data transmitted to the SEER program.
Staging for prostate cancer followed SEER conventions by using the tumor-node-metastasis system of the American Joint Committee on Cancer. We included the total serum PSA level (ng/mL) at baseline, which was defined as the closest value within 6 months before diagnosis. We obtained the twovalue summed Gleason score from the first biopsy leading to the PCa diagnosis. Using these three variables, we computed the American Urological Association (AUA) risk groups, which are categorized as low, intermediate, or high. 32 We ascertained the presence of 34 individual health conditions diagnosed between 2 years before PCa diagnosis to up to 3 months after PCa diagnosis (Appendix). For each condition, we required an inpatient diagnosis and/or at least two outpatient diagnoses codes at least 30 days apart to minimize false-positives. We used the 34 conditions when computing the propensity score. We also computed a simpler measure of comorbidity, the Elixhauser comorbidity index, 2 years before the PCa diagnosis date using the same strategy to avoid rule-out diagnoses.
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Statistical Analysis
We used the Cox proportional hazards regression model and fit four separate models to estimate the associations between PADT and each mortality outcome. For each model, follow-up time began on the date of diagnosis with death as the outcome event, and censoring corresponded to loss to follow-up (disenrollment) or end of the study period (December 31, 2010), whichever occurred first. For each outcome, we adjusted for patient sociodemographic and clinical prognostic factors and the 34 individual comorbidities in the multivariable models.
Because receipt of PADT was strongly associated with patient characteristics, we used a propensity score analysis to better balance covariates for the two PADT groups (Appendix Fig A2, online only) . We repeated the Cox proportional hazards model analyses with propensity score weighting (and standardized mortality ratio [SMR] weights) and propensity score matching approaches using separate models to assess the mortality risk associated with PADT versus no-PADT for each of the four mortality outcomes.
Subgroup Analysis
We conducted stratified analyses by AUA risk groups and age groups to assess whether the association of PADT and mortality differed among clinical subgroups. AUA risk groups were defined as: low (pretreatment PSA level, Յ 10 ng/mL; Gleason score, Յ 6; clinical stage, Յ T2a); intermediate (PSA, 10 to Յ 20 ng/mL; Gleason score, 7; clinical stage, T2b); or high (PSA, Ͼ 20; Gleason score, 8 to 10; clinical stage, T2c-T3a). We classified age at PCa diagnosis into three age groups, younger than 65 years, 65 to 74 years, and Ն 75 years. Separate models were created to estimate the adjusted risk of all-cause and cause-specific mortality for each subgroup, adjusting for propensity score SMR weights. We describe methods for handling missing data in the Appendix.
RESULTS
Population Characteristics
The cohort included 15,170 men who were newly diagnosed with localized PCa and did not receive curative intent therapy; 23% of the men had PADT initiated within the first year after diagnosis. Men who received PADT had worse prognostic factors ( Table 1 ). The PADT group had higher PSA levels (42% v 10% for PSA Ͼ 20) and higher Gleason scores (26% v 7% for Gleason score Ն 8) than the no-PADT group. Thus, 58% of men receiving PADT were in the AUA-defined high-risk group, versus just 18% of the no-PADT group who were categorized as high risk. The PADT group had more comorbidities (per Elixhauser index) than the no-PADT group (31% v 24% for at least three major comorbidities). After adjusting for propensity score, differences in all of the sociodemographic and clinical characteristics achieved balance (Appendix). 
Analysis of Mortality Outcomes
There were 4,921 deaths in the cohort, of which 1,049 deaths (32%) were related to prostate cancer ( Table 2 ). The median follow-up time was 54 and 64 months in the PADT and no-PADT groups, respectively. Men who received PADT versus men who did not experienced a nearly two-fold increase in all-cause mortality (49% v 28%; hazard ratio [HR], 1.96; 95% CI, 1.85 to 2.08) and a nearly three-fold increase in prostate cancer-specific mortality (13% v 5%; HR, 2.91; 95% CI, 2.57 to 3.28), without adjustments for other variables. Using a Cox proportional hazards model without propensity score adjustment, PADT was not associated with the risk of all-cause mortality (HR, 1.04; 95% CI, 0.97 to 1.11) nor the risk of PCa mortality (HR, 1.03; 95% CI, 0.89 to 1.19), after adjusting for all other covariates. Propensity score adjustment did not materially alter the risk estimates from the conventional models (with all HRs closer to 1.0; Table 2 ). Because we included men diagnosed with prior or subsequent cancers other than prostate cancer, we looked at deaths from any cancer ( Table 2 ) and observed no difference in mortality between the PADT and no-PADT groups. We observed an increased risk of cardiovascular deaths in the PADT group (13% v 8%; unadjusted HR, 1.81; 95% CI, 1.61 to 2.02), but this difference decreased after adjustment and was not statistically significant (HR, 1.11; 95% CI, 0.95 to 1.27). Adjusted results were similar in analyses of men who received prostatectomy after 12 months (n ϭ 295; presumably as delayed, curative intent therapy) in censored observations (not shown). Using sensitivity analyses, we found that these results did not materially differ from the subset of complete cases, that is, those men whose records included complete information on baseline PSA, Gleason score, and stage. Table 3 lists results from the conventional Cox proportional hazards model for our two primary outcomes. Other risk factors associated with all-cause and PCa death included older age, advanced stage, higher baseline PSA, higher Gleason score, and advanced tumor stage.
In the subgroup analyses (Table 4) , we found no differential effects by age on the association of PADT with either all-cause or cause-specific mortality. However, we observed that the AUA risk group modified the relationship between PADT and the risk of allcause mortality. Using Cox proportional hazards models with propensity score SMR weighting for each subgroup, PADT was associated 
DISCUSSION
Using PADT to treat clinically localized prostate cancer has not been proven effective in any subgroup of men; it neither to reduces risk of PCa progression nor mortality, which is typically preceded by disease progression to symptomatic, castration-resistant metastatic disease. Given the uncertain risk-benefit ratio for PADT and the fact that no trials are ongoing or planned to address this gap, we designed a retrospective cohort study to compare the mortality risk for PADT versus no PADT among men with clinically localized prostate cancer. We found no significant difference in the risk of all-cause mortality, prostate cancer-specific mortality, cancer mortality, or cardiovascular mortality between the PADT and no-PADT groups. Our results used conventional modeling approaches and paralleled the results observed when using the propensity score-weighting and propensity score-matching methods and, therefore, do not appear sensitive to the modeling approach.
Our main conclusion is that PADT does not seem to be an effective strategy as an alternative to no therapy among men diagnosed with clinically localized PCa who are not receiving curative-intent therapy. The risks of serious adverse events and the high costs associated with its use 16 mitigate against any clinical or policy rationale for PADT use in these men. Although we did not evaluate the risk of disease progression associated with PADT, a prior study using SEERMedicare data reported that early PADT treatment of low-risk localized PCa did not delay the receipt of subsequent secondary therapies and actually increased the use of subsequent chemotherapy for castration-resistant disease. 34 Interestingly, our subgroup analysis revealed a slightly reduced risk of all-cause mortality in the high-risk subgroup treated with PADT, a slightly elevated risk among the low-risk men receiving PADT, and no difference among intermediate-risk men receiving PADT. Our point estimate for the cause-specific mortality reduction associated with PADT (HR, 0.95) was not statistically significant but was consistent with the small protective and significant effect we observed for all-cause mortality. The nonsignificance of this result may be in part because of limited power, as only 7% of the cohort died from PCa, and in part because of possible misclassification of cause of death. However, the decision to prescribe PADT in high-risk men based on this result should be carefully weighed against the possible harms.
Reports on the risk of cardiovascular morbidity and mortality related to ADT are mixed. 35 We assessed whether there was an increased risk of cardiovascular mortality associated with PADT, but found no significantly increased risk in the PADT group versus the no-PADT group after adjustment for all other covariates, including pre-existing cardiovascular conditions. Further in-depth analysis of the risk of nonfatal cardiovascular events is ongoing using this cohort and will be reported separately.
Our results are consistent with three previous studies of PADT that used the SEER-Medicare-linked database. Two studies found that, in general, PADT was not associated with improved survival rates in early-stage prostate cancer in men diagnosed from 1992 to 2002 who received follow-up through 2005 to 2006. 11, 30 Another study found an increased risk of death associated with PADT. 29 However, these studies examined patients older than 65 years and did not consider baseline PSA values or Gleason scores.
Two of these studies used an instrumental variables analysis (IVA) approach to account for unmeasured confounding.
11,30 Some subgroup findings differed; one study showed an increased risk of cause-specific death among the low-risk men 11 and another showed a protective effect of PADT on PCa-specific mortality in the high-risk men. 30 This latter finding is consistent with our finding in high-risk men who experienced some benefit in all-cause mortality after receiving PADT, although we did not observe any benefit in PCa-specific mortality rates. The use of IVA as the primary analytic strategy is limited because the results estimate the average effect only in those patients who vary regarding the instrument selected. This makes IVA less useful for clinical decisions because it does not provide an estimate of the effects of treatment in the treated versus not treated groups and, thus, is more suitable for informing policy rather than clinical decisions. Our study has several limitations that should be considered while interpreting our results. The most significant concern in treatmentoutcome studies is the possibility of residual confounding, particularly for factors that have implications for treatment choice and are related to the outcome. For example, we were unable to account for potentially important risk factors that were unavailable in our data, such as prediagnosis PSA doubling time or the presence of undetected distant metastases because most men in our cohort did not receive imaging tests as part of their initial diagnostic work-up. Statistical adjustments cannot fully account for clinical judgments that incorporate information on these and other unmeasured variables used to drive clinical decisions. We did not conduct a secondary analysis evaluating the effects of delayed ADT in our no-primary-ADT group because we lacked key information regarding the clinical reasons for implementing delayed ADT in our cohort. A second limitation is that our finding of a reduced risk of all-cause mortality in the high-risk subgroup may be spurious, because we did not adjust for multiple comparisons in our evaluation of two outcomes in 12 subgroups. Finally, our study may have limited generalizability because our study was limited to three large, integrated health plans. However, these health plans include a socioeconomically and racially diverse community population.
Our study's strength is its data richness, particularly with respect to clinical prognostic factors in contrast with prior SEER-Medicare studies. Our propensity score analysis used information from all measured covariates to balance observed factors between treatment groups. As long as there are relationships between unobservable and measured factors, propensity score analysis can also reduce the bias associated with unobserved factors. 36 Nevertheless, there is likely to be some unmeasured confounding that we are unable to control for.
In summary, we found that most men diagnosed with clinically localized PCa who do not receive curative-intent therapy receive no apparent mortality benefit from PADT compared with receiving no therapy. We did, however, find a small and statistically significant overall mortality benefit associated with PADT use in the subgroup of men with high-risk PCa. The observed benefit was relatively small and should not be taken as definitive, given the limitations of our data and the possibility of a spurious finding. Any actual benefit must be weighed against other evidence suggesting an increased risk of serious adverse effects of PADT. Because no randomized trials will likely ever definitively assess the utility of PADT, our study provides the best contemporary evidence available on the lack of survival benefit of PADT for most men with clinically localized prostate cancer.
AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The author(s) indicated no potential conflicts of interest. . Checking covariate balance after using propensity score as standardized mortality ratio (SMR) weights. This plot shows the standardized difference in the proportions (for binary variables) or means (for continuous variables) between the primary androgen-deprivation therapy (PADT) group and non-PADT group for each covariate, before matching (blue) and after adjusting (gold) for propensity score SMR weights, using one imputed data set. This is used to evaluate whether the standardized difference between groups on each variable is less than 10%, a conventional threshold for determining a meaningful difference. Before weighting, there are many variables with differences greater than 10%; after adjusting for propensity score weights, the differences by treatment group are all less than 10%, indicating balance has been achieved by use of these weights. AUA, American Urological Association; COPD, chronic obstructive pulmonary disease; HFHS, Henry Ford Health System; KPNC, Kaiser Permanente Northern California; PSA, prostate-specific antigen.
AUTHOR CONTRIBUTIONS
Mortality Following Primary ADT
www.jco.org
